---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115596"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-10-18T23:59:59+00:00"
generated_at: "2026-05-30T12:49:17.633206+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics CSO Marc Van Dijk transitions to advisory roles effective Nov 15

## Summary
- Dr. Marc Van Dijk leaves Chief Scientific Officer role, becomes Scientific Advisory Board Member and Strategic Consultant.
- Transition effective November 15, 2024; Van Dijk to continue supporting programs and collaborations.
- No replacement for CSO announced; advisory roles indicate retained expertise.

## SEC filing metadata
- accession: 0000950170-24-115596
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-10-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000095017024115596/0000950170-24-115596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000095017024115596/inkt-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115596
- JSON: https://secwatch.observer/filing/0000950170-24-115596.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115596.txt

## Key facts
- Executive change
  Dr. Marc Van Dijk changed role as Chief Scientific Officer at MiNK Therapeutics, Inc..
  - Action: transitioned from
  - Role: Chief Scientific Officer
  source text: Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000095017024115596/0000950170-24-115596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.